- Article
- Source: Campus Sanofi
- 23 Oct 2023
How Nexviadyme®▼ (avalglucosidase alfa) was designed
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/How-Nexn-was-designed_2.jpg/jcr:content/How%20Nexn%20was%20designed_2.jpg)
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
This video outlines the development process for Nexviadyme®. Find out how we used preclinical mice models of Pompe to help design Nexviadyme®, and ultimately, improve maintenance of muscle strength compared to Myozyme®.1,2
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/1-larg-card-green-mom.jpg/jcr:content/1%20larg%20card%20green%20mom.jpg)
Our commitment to rare diseases
Find out how we have led with science for over 30 years,3 and continue to bring innovation to people living with lysosomal storage disorders.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/card-2-violet.jpg0/jcr:content/card%202%20violet.jpg)
Why Nexviadyme® was developed
From the challenges of cell delivery, to optimising targeting,2,4 explore why Sanofi developed Nexviadyme®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/1-larg-card-green-mom.jpg/jcr:content/1%20larg%20card%20green%20mom.jpg)
Our commitment to rare diseases
Find out how we have led with science for over 30 years,3 and continue to bring innovation to people living with lysosomal storage disorders.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/card-2-violet.jpg0/jcr:content/card%202%20violet.jpg)
Why Nexviadyme® was developed
From the challenges of cell delivery, to optimising targeting,2,4 explore why Sanofi developed Nexviadyme®.
References
- Sanofi. Nexviadyme (avalglucosidase alfa). Summary of Product Characteristics. 2023. Available at: https://www.medicines.org.uk/emc/product/14562/smpc#gref.
-
Zhu Y, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Molecular Therapy. 2009 Jun;17(6):954-963.
- Mistry, P.K. et al. Rare lysosomal disease registries: lessons learned over three decades of real-world evidence. Orphanet Journal of Rare Diseases. 2022;17:362.
-
Zhu Y, et al. Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. The Biochemical Journal. 2005 Aug 1;389(Pt 3):619-628.
-
Chien YH, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. Journal of Pediatrics. 2015 Apr;166(4):985-91.e1-2.
MAT-XU-2302278 (v3.0) Date of preparation: December 2023